What systemic therapy would you choose for elderly patients with HER2+ breast CA who have early metastatic relapse (within months) of completing adjuvant trastuzumab/paclitaxel?  

What would you offer if the patient is not a candidate for cytotoxic therapy?



Answer from: Medical Oncologist at Academic Institution